A single dose of respiratory syncytial virus vaccine was effective against infections and associated hospitalizations in veterans aged at least 60 years during the 2023-24 season.

GSK's vaccine against respiratory syncytial ... GSK revealed the results from its pivotal AReSVi-006 trial of the RSV shot - called RSVPreF3 OA - having said earlier this year that the study ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

The risk for new-onset or recurrent AF was not increased among older adult patients with preexisting conditions following RSV vaccination.

Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...

Led by researchers at the Wesfarmers Center of Vaccine and Infectious Diseases, based at The Kids Research Institute Australia, the REVIVE Study investigated RSV-related hospital admissions ...

READ MORE: NHS Covid vaccine appointments now available to book Dr Alasdair Wood, consultant in health protection at UKHSA South West, said: "Our analysis clearly demonstrates the excellent benefit of ...